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ABSTRACT
Acute graft-versus-host disease (aGVHD) remains one of the main obstacles after allogeneic bone marrow
transplantation (BMT). Using a well-established mouse BMT model in which aGVHD is induced across a
haploidentical mismatch, we show that the expression of heme oxygenase-1 (HO-1) can be induced by
cobalt-protoporphyrin IX (CoPP) in aGVHD target organs such as liver and bowel and that the induction of
HO-1 before BMT results in improved overall survival and reduced aGVHD. Serum levels of proinflammatory
cytokines were markedly reduced in CoPP-treated animals. Recipients displayed less damage to the intestinal
mucosa, and this resulted in reduced serum lipopolysaccharide levels at day 6 after transplantation. Peritoneal
cells and CD45 liver cells isolated from mice that received transplants strongly expressed HO-1 and displayed
a reduction in the expression of activation markers such as CD11b, CD80, and major histocompatibility
complex class I. This resulted in reduced T-cell activation ex vivo. These results demonstrate that the
induction of HO-1 before high-dose conditioning protects the host in multiple ways and effectively ameliorates
aGVHD.
© 2004 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
n important therapeutic option for a number of ma-
ignant and nonmalignant hematopoietic disorders.
nfortunately, the utility of BMT is limited by several
omplications, including acute graft-versus-host dis-
ase (aGVHD), which remains the major cause of
ortality after transplantation. The pathophysiology
f aGVHD is believed to be a multistep process that
nvolves conditioning-related toxicity, activation of
onor T cells that recognize major histocompatibility
omplex (MHC), the presentation of alloantigens by b
B&MTost antigen-presenting cells (APC), and the release of
roinﬂammatory cytokines [1,2]. Activation of donor
cells results in their proliferation and differentiation
nd eventually leads to tissue damage in aGVHD
arget organs such as liver, gut, and skin [3,4]. In
ddition to tissue damage by T cells, proinﬂammatory
ytokines such as tumor necrosis factor (TNF)– and
nterferon (IFN)–, released by various cells, includ-
ng host APCs, contribute to the process [5-7]. This
nﬂammatory response is propagated by the leakage of
acterial lipopolysaccharide (LPS) across bowel mu-
osa damaged initially by BMT conditioning and later
y aGVHD; LPS is a potent cellular activator, and
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4PS stimulation results in an increased proinﬂamma-
ory cytokine release and an enhanced allostimulatory
apacity of APCs.
The role of BMT conditioning in initiating the
nﬂammatory events that contribute to the develop-
ent of aGVHD and other transplant-related com-
lications has prompted investigators to develop and
est reduced-intensity preparative regimens. Unfortu-
ately, several underlying diseases require full-inten-
ity conditioning; thus, protection of the host against
he injurious effects of radiochemotherapy could re-
ult in reduced GVHD.
The stress-inducible protein heme oxygenase-1
HO-1), which catalyzes the rate-limiting step in
eme degradation to biliverdin [8], has been identiﬁed
s a protein with anti-inﬂammatory and antiapoptotic
roperties [9-12]. The enhanced expression of HO-1
esults in local downregulation of inﬂammation and,
n case of solid organ transplantation, leads to a pro-
onged graft survival [10,13-16]. Additionally, HO-1
as been implicated in the cytoprotective response
gainst irradiation and apoptosis-inducing cytokines
uch as TNF- [11,17,18] and is believed to mediate
nti-inﬂammatory effects of interleukin (IL)–10 in
ice [19]. We therefore hypothesized that enhanced
xpression of HO-1 before and after allogeneic BMT
ould abrogate the development of aGVHD. HO-1
an be induced in a variety of tissues by its natural
ubstrate heme and other synthetic metal porphyrins,
uch as cobalt-protoporphyrin IX (CoPP) and zinc-
rotoporphyrin IX (ZnPP). Induction of HO-1 func-
ion is dependent on the central metal atom of the
orphyrin, and in case of ZnPP, HO-1 function is
locked because the substrate cannot be enzymatically
egraded [20,21]. We tested our hypothesis by using a
ell-described high-dose conditioning murine BMT
odel [22] in which aGVHD is characterized by in-
ammatory cytokine release and signiﬁcant injury to
he intestinal tract within the ﬁrst week after BMT.
ur results show that induction of HO-1 by CoPP in
ecipient mice before conditioning and BMT results
n a reduction of GVHD and improved survival.
VHD reduction by HO-1 is mediated by a reduc-
ion in the production of proinﬂammatory cytokines,
y injury to the gut, and by the allostimulatory capac-
ty of host-derived APCs.
ATERIALS AND METHODS
ice, BMT, and Assessment of GVHD
The protocol for BMT and GVHD induction has
een described previously [23]. Brieﬂy, female
6D2F1 (H-2bxd), C57BL/6 (H-2b), and CBA (H-2k)
ice were purchased from Charles River Laboratories
Sulzbach, Germany) and underwent transplantation
ketween the ages of 10 and 20 weeks. B10.BR (H-2 ) a
62onor mice were bred in our facility. Animals were
oused according to German animal protection laws
nd protocols of the local committee. Bone marrow
as harvested from the femurs and tibias of donor
ice. Cell mixtures of erythrocyte-lysed 5 106 bone
arrow cells were supplemented with 1  106 splenic
ells from either syngeneic (B6D2F1, CBA) or allo-
eneic (C57BL/6, B10.BR) donors, resuspended in
eibovitz L-15 medium (Life Technologies, Grand
sland, NY) and transplanted into B6D2F1 (CBA)
ecipients via tail vein infusion (0.25 mL total vol-
me). Before transplantation, host mice received 14
y (or 11 Gy in case of CBA recipients) of total body
rradiation (accelerator, 150 cGy/min) delivered in 2
ractions, separated by 3 hours, to reduce gastrointes-
inal toxicity. Mice were subsequently housed in ster-
lized microisolator cages and received normal chow
nd autoclaved hyperchlorinated water for the ﬁrst 2
eeks after BMT and ﬁltered water thereafter. For
O-1 induction, recipient mice received 125 g of
oPP intraperitoneally at day 2 and 1 before con-
itioning (day 0) and at transplantation. Control mice
eceived phosphate-buffered saline (PBS) alone.
The severity of GVHD was assessed by a previ-
usly described clinical scoring system, which incor-
orates 5 parameters: weight loss (recipient mice were
ar-punched, and individual weights were obtained
nd recorded on day 1 and weekly thereafter), pos-
ure (hunching), activity, fur texture, and skin integrity
22,24]. Mice from coded cages were evaluated
eekly, and changes were graded from 0 to 2 for each
riterion. A clinical index was subsequently generated
y summation of the 5 criteria scores (maximum, 10).
urvival was assessed daily after transplantation. Ac-
ording to German animal protection laws and local
rotocols by the committee, animals showing a
VHD score greater than 6 were killed and added to
aplan-Meier statistics the same day.
nduction of HO-1
CoPP or ZnPP (Frontier Scientiﬁc Porphyrin
roducts, Logan, UT) was prepared in dim light be-
ause of the light sensitivity of the compounds. CoPP
as dissolved in sodium hydroxide, and the pH was
ubsequently adjusted to 7 by adding equal amounts of
ydrochloric acid. The ﬁnal pH of 7.4 was achieved by
urther dilution with PBS. Before injection, pH was
onﬁrmed by using a pH meter (WTW, Weilheim,
ermany). In control experiments, animals that re-
eived CoPP or ZnPP (to induce HO-1 protein but
lock HO-1 function) did not show any signs of tox-
city such as hunching or reduction in mobility, nor
ere any effects of CoPP/ZnPP observed in treated
nimals over several weeks.
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Heme Oxygenase-1 in Allogeneic Bone Marrow Transplantation
Breparation of Peritoneal Macrophages and
ulture
Mice were killed with CO2, and the peritoneal
avity was ﬂushed subsequently 3 times with 5 mL of
PMI 1640 media supplemented with 10% fetal calf
erum (FCS) and antibiotics. Cells were washed twice,
ounted, and plated in round-bottomed 96-well plates
Corning Costar, Wiesbaden, Germany).
reparation of CD3 Splenic T Cells
One milliliter of collagenase H (1 mg/mL) in
PMI 1640 standard medium was injected into
pleens and incubated for 1 hour at 37°C. Spleens
ere then carefully dissolved between glass slides and
ltered over a 70-m cell strainer (Falcon, Le Pont de
laix, France). Cells were incubated in 10% PBS/FCS
nd incubated with biotinylated antibodies against
220, Ter119, Gr-1, and CD11b. Cells were washed
nd subsequently incubated with streptavidin mi-
robeads (Miltenyi, Bergisch Gladbach, Germany)
nd sorted according to the manufacturer’s protocol.
he purity of the negative fraction was determined by
ow cytometric analysis with phycoerythrin (PE)–
onjugated or ﬂuorescein isothiocyanate (FITC)–con-
ugated antibodies against CD3, CD4, and CD8.
reparation of CD45 Liver Cells
Liver tissue was minced with scalpels and further
issolved by a short collagenase H (1 mg/mL) treat-
ent at 37°C in standard RPMI 1640 medium for 30
inutes. Tissue was further dissolved by subsequent
igorous pipetting and ﬁltered through a 70-m cell
trainer. The single-cell suspension was incubated
ith 10% PBS/FCS at 4°C for 30 minutes and sub-
equently incubated with anti-CD45 PE-conjugated
ntibody. Cells were isolated by using anti-PE mi-
robeads according to the manufacturer’s protocol
Miltenyi).
ytokine and LPS Analysis
Serum and culture supernatant levels of cytokines
ere analyzed with commercially available enzyme-
inked immunosorbent assay kits (Biosource, Nivelle,
elgium) according to the manufacturer’s protocol.
erum samples were diluted 50%, and culture super-
atants were used undiluted. LPS quantiﬁcation was
erformed with the QCL1000 test kit (BioWhittaker,
alkersville, MD).
ntibodies Used
Rabbit anti-mouse HO-1 (SPA-895; StressGen,
ictoria, Canada), anti–-actin (A2066; Sigma,
hemicals, Taufkirchen, Germany), anti-rabbit im-
unoglobulin horseradish peroxidase antibody, anti-
abbit immunoglobulin FITC (DAKO, Hamburg, i
B&MTermany), PE- or FITC-conjugated anti-mouse
D45 (clone 30.F11), MHC class I (clone AF6-88-5),
D80 (clone 16-10A1), CD86 (clone GL1), CD3
clone 145-2c11), CD4 (clone RM4-7), CD8 (clone
3-6.7), biotinylated anti-mouse Gr-1 (clone RB6-
C5), CD45R/B220 (clone RA3-6B2), TER119
clone TER119), and CD11b (clone M1/70) were
btained from Becton Dickinson (Heidelberg, Ger-
any).
estern Blot Analysis
All reagents and chemicals were purchased from
oche (Mannheim, Germany) or Sigma. Cell pellets
ere washed in wash buffer (40 mmol/L Tris-HCl,
.3 mmol/L NaCl, 2 mmol/L ethylenediaminetet-
aacetic acid [pH 8], 1 mmol/L phenylmethylsulfonyl
uoride, 2 g/mL aprotinin, 0.5 g/mL leupeptin, 0.5
mol/L sodium orthovanadate, and 0.2 mmol/L so-
ium ﬂuoride). After washing, cells were lysed in lysis
uffer (wash buffer plus 1% Nonidet P-40 [Roche,
asel, Switzerland]) for 30 minutes at 4°C and were
hen centrifuged at 16000g for 15 minutes. An aliquot
f the supernatant was used for determination of the
rotein concentration by the Biuret method. The pro-
ein solution was mixed 1:1 with 2 Laemmli buffer
20% glycerol, 4% sodium dodecyl sulfate, 10%
-mercaptoethanol, 0.02% bromphenol blue, and
.25 mmol/L Tris, pH 6.8), and sodium dodecyl sul-
ate-polyacrylamide gel electrophoresis was per-
ormed with equal amounts of protein. After separa-
ion at 130 V for 2 hours, proteins were transferred to
nitrocellulose membrane (Amersham Pharmacia
iotech, Freiburg, Germany). To avoid unspeciﬁc
rotein binding, membranes were blocked with 5%
ry milk in Tris-buffered saline with 0.1% Tween 20
TBST) for 1 hour at room temperature, washed, and
hen incubated with anti–HO-1 antibody (SPA-895)
nd anti–-actin antibody (A2066) in 5% dry milk/
BST overnight at 4°C. The blots were washed 3
imes and incubated with anti-rabbit immunoglobulin
orseradish peroxidase antibody (P0448; DAKO) in
% dry milk/TBST for 1 hour at room temperature.
mmunoreactive bands were developed by using an
nhanced chemoluminescence kit (Amersham Phar-
acia Biotech).
mmunohistochemistry
Tissue sections (5 m) of frozen tissue or cyto-
pins of isolated cells were ﬁxed in 2% paraformalde-
yde for 5 minutes at room temperature, washed in
BS, and incubated with 10% FCS and 5% swine
erum for 30 minutes at room temperature. Slides
ere then incubated with anti–HO-1 antibody (1:200
ilution) for 60 minutes at room temperature. Stain-
ng was visualized by using FITC-labeled anti-rabbit
mmunoglobulin G (DAKO). Sections were embed-
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4ed in ﬂuorescence mounting media (DAKO) and
nalyzed with a Carl Zeiss (Go¨ttingen, Germany) Ax-
oskope microscope and Zeiss Axiocam together with
xiovision software.
ixed Lymphocyte Reaction
T cells were prepared by negative selection by
sing MiniMacs (Miltenyi) sorting columns, and pu-
ity was determined by subsequent ﬂow cytometric
nalysis with directly labeled antibodies against CD3,
D4, and CD8. Purity was generally 85%. Equal
umbers of T cells (200000 per well) were then plated
n quadruplicate in 96-well plates (ﬂat bottom) and
timulated with irradiated (30 Gy) CD45 liver cells
100000 per well) from allogeneic B6D2F1 donors
hat received intraperitoneal CoPP or PBS 24 hours
efore preparation. After 48 hours of re-stimulation,
H-thymidine was added to the culture, and prolifer-
tion activity was assessed by a microplate scintillation
ounter (Packard Canberra, Dreieich, Germany) after
4 hours. Data are expressed as the mean counts per
inute per well. For positive control, syngeneic
C57BL/6-derived stimulators) stimulated T cells re-
eived concanavalin A at a concentration of 2.5
g/mL 12 hours before 3H-thymidine.
low Cytometric Analysis
Cells were washed in freshly prepared cold
BS/5% FCS and incubated with 10% supernatant
rom clone 2.4G2 to block Fc receptors for 30 min-
tes on ice. Then, directly FITC- or PE-labeled
onoclonal antibodies (H-2k, I-A, CD80, CD86,
D4, CD8, CD3, CD11b, and CD11c) were applied
nd incubated for 30 minutes on ice. Cells were
ashed twice in cold PBS/FCS and subsequently an-
lyzed by FACScan (Becton Dickinson).
issue Procurement and Examination of Histology
Mice were killed by CO2, and organs were re-
oved and placed into OCT Tissue Tek (Miles,
lkhart, IN) and snap-frozen in dry ice–cooled buta-
ol. Organs were stored at 80°C. In some experi-
ents, organs were ﬁxed in 10% buffered formalin,
mbedded in parafﬁn, and cut into 5-m-thick sec-
ions. Sections were stained with hematoxylin and
osin according to standard practice.
Coded small-bowel sections were scored by T.S.
he scoring system includes 4 parameters from 0 to 2
apoptosis, number of villi, number of Paneth cells,
nd number of mitoses per high-power ﬁeld), giving
ise to maximum score of 8.
tatistical Considerations
All values are expressed as the mean 	 SEM.
tatistical comparisons between groups were con-
ucted with the nonparametric unpaired Mann-Whit- m
64ey test unless otherwise speciﬁed. For survival
urves, Kaplan-Meier estimates were used.
ESULTS
VHD Target Organs Express HO-1 after the
dministration of CoPP
Several studies have demonstrated that the ex-
ression of HO-1 can be induced in a variety of
issues, such as endothelium, lung, and kidney
10,12,14,16,25]. We ﬁrst determined whether the
dministration of CoPP could enhance the tissue ex-
ression of HO-1 in GVHD target organs. B6D2F1
nimals were injected intraperitoneally with 125 g of
oPP on 2 consecutive days. Sections of liver and
ntestine were analyzed for HO-1 expression by im-
unohistochemistry 48 hours after the ﬁrst injection,
s described in Materials and Methods. In these ex-
eriments, splenic tissue served as a positive control
ecause HO-1 is constitutively expressed in the spleen
ecause of the natural abundance of its substrate heme
Figure 1A, left panel). HO-1 was expressed predom-
nantly within the red pulp where activated macro-
hages reside. As shown in the middle panel of Figure
A, endogenous expression of HO-1 was not observed
n liver or small-bowel tissue after treatment with
BS. In contrast, HO-1 was readily apparent in cells
esiding between hepatocytes after the injection of
oPP; HO-1 expression was evenly distributed and
urrounded central veins. Increased expression of
O-1 was conﬁrmed by Western blotting with liver
ell extracts (Figure 1A). Similar expression patterns
ere observed in the small bowel, where the distribu-
ion of HO-expressing cells was more patchy and
rganized in discrete groups of cells (Figure 1A, right
anel).
he Administration of CoPP Significantly Reduces
he Severity of aGVHD
We next determined the effects of enhanced
O-1 expression after CoPP administration on the
everity of aGVHD after allogeneic BMT. B6D2F1
ice received BMT from either allogeneic (B6) or
yngeneic (B6D2F1) donors after 1400 cGy of TBI.
nimals from each group were injected with either
oPP or control (PBS) on days 2 and 1, as de-
cribed previously. As expected, all syngeneic BMT
ecipients with or without CoPP survived (Figure 2A)
nd, after transient weight loss after TBI, showed no
igns of GVHD (Figure 2B). In contrast, control-
reated allogeneic BMT recipients died rapidly from
GVHD between days 7 and 21, and mortality was
00% by day 56 after BMT (Figure 2A). The admin-
stration of CoPP resulted in nearly complete abroga-
ion of aGVHD mortality; approximately 90% of
ice in the allogeneic group survived at day 63. Fur-
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Heme Oxygenase-1 in Allogeneic Bone Marrow Transplantation
Bher evaluation revealed that the clinical scores of mice
reated with CoPP were also signiﬁcantly reduced on
ay 14 and day 21 (P 
 .05) compared with controls.
urviving mice in this group did, however, develop
igns of GVHD over time, mainly reﬂected by alter-
tions in skin integrity and fur texture, although the
everity of aGVHD remained stable through day 63.
espite signs of GVHD, no additional deaths oc-
urred. This underscores the signiﬁcance of prevent-
ng early toxicity from GVHD. As an additional con-
rol, some animals from each group were treated with
nPP, a substrate that induces HO-1 protein expres-
ion but blocks HO-1 function, and no differences in
GVHD were noted when compared with PBS-
reated animals. This underscores the role of en-
anced HO-1 function in reducing GVHD (data not
hown). In a different model of aGVHD (B10.BR
nto CBA) in which GVHD is induced across mul-
iple minor mismatches, similar results were ob-
erved. Animals received lower conditioning with
1 Gy of total body irradiation and underwent
ransplantation as described previously. When
reated with CoPP before transplantation, 61% of
he mice survived at day 42, as compared with 16%
igure 1. Induction of HO-1 in GVHD target organs and macropha
arget tissue. Naive mice were injected twice intraperitoneally with
njection and evaluated for HO-1 expression, as indicated by the g
30. B, Western blotting of cellular extracts from liver or spleenurvival in the PBS-treated control group. GVHD (
B&MTcoring was also reduced on day 28 from 3.9 	 0.5
o 2.0 	 0.5 (P 
 .08) in the CoPP-treated group.
n contrast to the haploidentical BMT model, early
ortality between day 7 and 14 was similar in both
roups. However, PBS-treated animals showed pro-
ressive GVHD and, therefore, higher mortality,
hereas CoPP-treated animals remained stable,
ith a low GVHD score of approximately 2.
dministration of CoPP Significantly Reduces
erum Levels of Proinflammatory Cytokines
fter Allogeneic BMT
Previous studies using this BMT model have
emonstrated a critical role for proinﬂammatory
ytokine release in the development of aGVHD
22,23,26]. We therefore measured serum levels of
NF-, IL-1, IFN-, and IL-12 between day 4
nd 6 after BMT, a time point that heralds the onset
f mortality from GVHD in this system. As shown
n Figure 3, serum TNF- (48.6 	 5.0 pg/mL
ersus 26.9 	 3.8 pg/mL; P 
 .002) and IL-12
26.3 	 4.6 pg/mL versus 3.0 	 0.7 pg/mL; P 

002) levels were markedly reduced in CoPP-treated
nimals compared with allogeneic controls. IFN-
The administration of CoPP increased HO-1 expression in GVHD
g of CoPP or PBS. Organs were harvested 48 hours after the ﬁrst
orescence. Original magniﬁcation: spleen, 400; liver and bowel,
s conﬁrmed in situ HO-1 staining.ges. A,
125 
reen ﬂu
sample623 	 287 pg/mL versus 204 	 61 pg/mL; P 
 .13)
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4nd IL-1 (14.1 	 3.9 pg/mL versus 7.0 	 2.3
g/mL; P  .13) levels were also reduced but did
ot reach statistical signiﬁcance at the 5% level.
owever, serum IL-10 levels were signiﬁcantly in-
reased in allogeneic BMT recipients treated with
oPP compared with controls (39.9 	 5.2 pg/mL
ersus 19.1 	 4.5 pg/mL; P 
 .05). Consistent with
revious work in this system, serum cytokine levels
n syngeneic controls were below the limit of de-
ection for the enzyme-linked immunosorbent assay
igure 2. Reduction of GVHD and improved survival after transpl
r PBS on days 2 and 1 before 14 Gy of irradiation and BMT
. Mice were then monitored daily for survival and weekly for G
llogeneic BMT was also markedly improved in mice treated with C
ox; solid line; P 
 .01; Kaplan-Meier analysis). Syngeneic BMT re
ice with 2 doses of CoPP (triangles; solid line) before conditioning
038) and day 21 (*P  .024) when compared with control-treated a
esults from 1 of 5 independent experiments. CBA mice were treate
MT from either allogeneic (B10.BR) or syngeneic (CBA) donors o
BS-treated mice, solid square; P 
 .01; Kaplan-Meier analysis). D
how combined data from 3 independent experiments (12-18 animits used for this study (data not shown).
66dministration of CoPP Reduces Macrophage
ctivation and Allostimulatory Capacity
Macrophages are the principal source of inﬂam-
atory cytokine production after allogeneic BMT and
re also important APCs. We next evaluated the ex-
ression of HO-1 and activation markers on macro-
hages obtained from the peritoneal cavity and liver
ie, Kupffer cells) of animals that had undergone
ransplantation. On day 4 after BMT, peritoneal cells
arvested from allogeneic BMT recipients treated
n in CoPP-treated animals. B6D2F1 mice were treated with CoPP
ither allogeneic (C57BL/6) or syngeneic (B6D2F1) donors on day
score as described in Materials and Methods. A, Mortality after
iangles; solid line) compared with controls treated with PBS (square
that received CoPP or PBS all survived. B, Treatment of B6D2F1
ed in a signiﬁcant reduction of GVHD score between day 14 (*P 
(square box; solid line). The graphs (A and B) show representative
CoPP or PBS on days 2 and 1 before 11 Gy of irradiation and
. C, Mortality after allogeneic BMT (CoPP-treated mice, triangle;
D score after allogeneic BMT (#P 
 .08). The graphs (C and D)
group).antatio
from e
VHD
oPP (tr
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Heme Oxygenase-1 in Allogeneic Bone Marrow Transplantation
Bith CoPP readily expressed HO-1 (Figure 4A), as
hown by immunohistochemistry and Western blot.
orphologically, most of these cells were macro-
hages (data not shown), and nearly 100% of perito-
eal cells obtained from allogeneic control mice ex-
ressed CD11b (Figure 4B). Surprisingly, we
bserved a signiﬁcant reduction in CD11b expression
n CoPP-treated BMT mice. Because CD11b is also
onsidered an activation marker, we next looked at the
xpression of MHC class I and the co-stimulatory
olecules CD80 and CD86 and observed similar re-
uctions in cell-surface expression (Figure 4B). Com-
arable reductions in the expression of these activa-
ion markers were also noted in the CoPP group when
D45, HO-1–expressing cells from liver tissue were
solated at day 6 after BMT (data not shown). We next
etermined whether the administration of CoPP al-
ered the allostimulatory capacity of host APCs.
D45 liver cells were obtained from CoPP-, ZnPP-,
r PBS-treated naive B6D2F1 mice (Figure 4D) and
sed to re-stimulate splenic T cells collected on day 6
rom allogeneic BMT recipients. Liver cells (rather
han peritoneal cells) were chosen as stimulators to
ontrol for any direct toxic effect CoPP or ZnPP
igure 3. Proinﬂammatory serum cytokines were reduced in CoPP-
eceived BMT as described in Figure 2. Serum cytokines were
mmunosorbent assay according to the manufacturer’s protocol. Da
independent experiments).ight have on cells resident to the peritoneal cavity. T
B&MTs shown in Figure 4C, T-cell proliferation was re-
uced by 50% when the stimulator cells were obtained
rom CoPP-treated mice compared with control or
nPP-treated mice. However, the decrease in prolif-
rative response ex vivo was not associated with re-
uced IFN- or increased IL-10 production in culture
data not shown).
oPP Treatment Results in Lower Serum LPS
evels and Preservation of Small-Bowel Mucosa
The intestinal tract has been shown to be partic-
larly sensitive to the injurious effects of inﬂammatory
ytokines released during the induction of aGVHD
22,26,27]. We hypothesized that the reduction in
NF- levels would therefore be associated with a
eduction in the severity of gut GVHD. Samples of
mall bowel were harvested on day 6 after BMT and
nalyzed microscopically to generate an index of in-
ury as described in Materials and Methods. As shown
n Figure 5A, small-bowel sections from syngeneic
MT recipients (left panel) demonstrated re-estab-
ishment of near-normal intestinal architecture,
hereas sections from allogeneic BMT mice treated
ith PBS demonstrated severe signs of tissue damage.
animals. B6D2F1 mice were treated with either CoPP or PBS and
d between day 4 and 6 after transplantation by enzyme-linked
xpressed as mean 	 SEM (8 to 20 animals per group pooled fromtreated
analyze
ta are ehese changes included crypt destruction and drop-
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4ut, villous blunting, and surface erosion (middle
anel). By contrast, treatment with CoPP resulted in
igure 4. Peritoneal macrophages displayed reduced surface expre
6D2F1 mice were treated with CoPP or PBS on days 2 and 1
ay 0. Peritoneal cells were harvested and stained for HO-1 expressio
as enhanced in BMT recipients treated with CoPP, but not with
ntibody from macrophages treated with CoPP revealed a strong H
escribed previously, and were analyzed by ﬂow cytometry for surfa
ndicates cells from PBS-treated animals, and dotted lines represe
educed surface expression of macrophage markers such as CD11b
olecules such as CD80 were reduced. Filled histograms repre
xperiments). C, Freshly isolated CD45 liver cells were used to re
rom PBS- or ZnPP-treated mice induced a greater T-cell prolifera
nimals (P 
 .02). D, CD45 cells isolated from liver 48 hours aft
reated with CoPP or ZnPP displayed strong HO-1 expression, as
D45 expression on isolated cells. Original magniﬁcation, 630.reservation of small-bowel architecture, and only s
68ild crypt destruction and villous blunting was ob-
erved in these animals (right panel). When tissue
f activation markers and failed to stimulate allogeneic T cells. A,
lethal irradiation and allogeneic BMT from C57BL/6 donors on
scribed in Materials andMethods. Macrophage expression of HO-1
riginal magniﬁcation, 630. Western blotting of cellular extract
duction. B, Peritoneal cells were isolated on day 6 after BMT, as
ression of CD11b, MHC class I, CD80, and CD86. The solid line
PP-treated recipients. Cells from CoPP-treated mice displayed a
dition, MHC class I expression and expression of co-stimulatory
e isotype control antibody (representative results from 1 of 3
late allogeneic splenic T cells harvested at day 6 after BMT. Cells
ponse compared with stimulator cells obtained from CoPP-treated
nduction of HO-1 with CoPP, ZnPP, or PBS. Cells from animals
ted by the green ﬂuorescence. Orange surface staining representsssion o
before
n as de
PBS. O
O-1 in
ce exp
nt Co
. In ad
sent th
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Bsing a scoring system that includes 4 parameters as
igns of tissue alteration, pathology scores in CoPP-
reated animals were decreased compared with alloge-
eic controls (3.14 	 0.65 to 1.76 	 0.2; P  .07) and
ere reduced to the level observed after syngeneic
MT (Figure 5B). Endogenous LPS has been shown
o be an important trigger for inﬂammatory cytokine
elease after allogeneic BMT [28,29], and we mea-
ured serum LPS levels at day 4 to 6 after BMT. As
hown in Figure 5C, the protective effect that CoPP
dministration had on the intestinal tract was associ-
ted with a reduction in serum LPS levels in these
nimals compared with allogeneic controls (0.34 	
.03 versus 0.56 	 0.11; P 
 .001).
ISCUSSION
In this study we examined the effects of HO-1
nduction on the development of aGVHD by using a
ell-established mouse BMT model. HO-1 expres-
igure 5. Treatment with CoPP reduced intestinal GVHD and seru
oPP or PBS and received BMT as described in Figure 2. A, Sm
icroscopic analysis as described in Materials and Methods. Small
eceived transplants compared with controls, as indicated by les
ncorporated into a semiquantitative scoring system to generate an in
n CoPP-treated animals compared with allogeneic BMT recipient
est; 8 to 12 animals per group). C, Serum samples were collected b
imulus QL1000 test (BioWhittaker). Animals treated with CoPP b
re expressed as mean 	 SEM; Mann-Whitney test; 10 to 18 animion could be demonstrated in GVHD target tissue, S
B&MTncluding the liver and gut, within 48 hours of CoPP
njection. Induction of HO-1 before conditioning re-
ulted in a reduction in the severity of aGVHD, as
easured by mortality and clinical score. This protec-
ive effect was associated with signiﬁcant reductions in
nﬂammatory cytokine release, intestinal histopathol-
gy, and serum LPS levels. Additionally, the induction
f HO-1 after BMT was associated with a reduction in
he cell-surface expression of activation markers and
n the allostimulatory capacity of peritoneal and he-
atic macrophages.
Our results demonstrate that the induction of
O-1 before conditioning with 1400 cGy of TBI has
signiﬁcant effect on overall survival and aGVHD
fter allogeneic BMT. The reduction of aGVHD in
ur model may be attributed to interactions with sev-
ral aspects of GVHD pathophysiology. As described
y Hill et al. [22,23], the development of aGVHD is
elieved to be a multistep process initiated by diffuse
issue injury caused by BMT conditioning regimens.
levels after allogeneic BMT. B6D2F1 mice were treated with either
el samples were harvested on day 6 after BMT and prepared for
architecture was preserved in CoPP-treated allogeneic mice that
s blunting and crypt destruction. B, Microscopic features were
injury. Mean small-bowel pathology scores were signiﬁcantly lower
d with PBS. (Data are expressed as mean 	 SEM; Mann-Whitney
days 4 and 6 after BMT and were analyzed for LPS by using the
onditioning displayed signiﬁcantly reduced serum LPS levels (data
group from 3 independent experiments).mLPS
all-bow
-bowel
s villou
dex of
s treate
etween
efore ceveral studies in humans and in mice have revealed
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4he connection between high doses of irradiation and
he development of aGVHD, and these have led to
he development of reduced-intensity condition-
ng regimens to prevent damage to the host and the
oncurrent release of proinﬂammatory cytokines
3,22,30,31]. Only a few studies have been completed
o reduce conditioning-induced damage by protecting
he host tissue [32,33]. Our data suggest that the
ffects of HO-1 induction are related in part to the
rotection of BMT recipient mice against damage
rom TBI, particularly with respect to radiation-sen-
itive organs such as the small bowel; reduced intesti-
al injury was associated with signiﬁcant reductions in
erum LPS levels. Several studies have demonstrated
hat the induction of HO-1 can prevent irradiation-
nduced programmed cell death [10,12,17]. In partic-
lar, HO-1 induction in endothelial cells protects the
ndothelium from various stress signals, including ir-
adiation [34-37]. Endothelial cell damage, in partic-
lar, has been suggested recently as the primary lesion
uring the initiation of gut damage after irradiation
38].
The transplantation model used in these experi-
ents is characterized by a strong release of proin-
ammatory cytokines such as TNF-, IL-1, and
FN-, which are signiﬁcant contributors to GVHD
arget organ injury [2,22,26,39]. The induction of
O-1 by CoPP before conditioning signiﬁcantly re-
uced serum levels of TNF- and IL-12 and effec-
ively prevented the early mortality seen in this sys-
em. In addition, the administration of CoPP before
MT was associated with a signiﬁcant increase in
L-10 levels. Polarization of T cells toward a T-helper
ype 2 phenotype has resulted in improved survival
fter allogeneic BMT in several studies [23,40-42], but
t remains to be determined in our studies whether the
ncreased serum levels of IL-10 are a result of a shift in
ytokine release by macrophages, T-cells, or both.
he role of IL-10 after allogeneic BMT has been a
ubject of considerable interest. IL-10 is known to
ave “tolerogenic” effects on T cells when present in
mixed lymphocyte reaction together with monocytes
43-45]; it downregulates MHC class I and II expres-
ion on APCs and effectively suppresses T-cell prolif-
ration and IFN- production. However, several
roups have shown that the administration of IL-10
efore and after allogeneic BMT can result in mixed
utcomes [7,42,46-49]. In a study pertinent to our
ork, Lee and Chau [19] recently demonstrated that
he anti-inﬂammatory effects of IL-10 in mice are
ediated at least in part by HO-1. They demon-
trated that HO-1 was induced by IL-10 and pre-
ented macrophages from releasing TNF- in re-
ponse to LPS stimulation. The reduction in serum
NF- levels in allogeneic BMT recipients treated
ith CoPP is in accord with this study.
In a previous publication, the effect of HO-1 in- n
70uction on GVHD was explored by inducing HO-1 in
he donor rather than the recipient [50]. Those au-
hors used the same mouse strain combination, but it
s important to note that BMT recipients did not
eceive any conditioning and that large doses of
plenocytes were used to induce GVHD. The authors
eported a decrease in the spontaneous release of
FN- and IL-2 and an increase in the spontaneous
elease of IL-10 when splenocytes harvested after
MT where cultured in vitro. Although these data
uggest that HO-1 induction in BMT donors can
olarize T cells toward a T-helper type 2 phenotype,
he authors were not able to link improved survival or
istologic changes in GVHD target organs to alter-
tions of cytokine production in vivo. In contrast to
he observations of Woo et al. [50], we did not observe
ny changes in ex vivo cytokine proﬁles despite the
eduction of the proliferative response when macro-
hages from CoPP-treated animals were used as stim-
lators in a mixed lymphocyte reaction. In addition,
e did not observe any differences in spleen size or
plenocyte numbers after BMT. This shows that the
dministration of CoPP to BMT recipients reduced
VHD without signiﬁcantly impairing donor T-cell
xpansion after transplantation. This point is exempli-
ed by our observations that aGVHD was not com-
letely abolished by the administration of CoPP; sur-
iving mice displayed signs of aGVHD over the entire
ime of observation, as indicated by our GVHD scor-
ng system. These ﬁndings have important ramiﬁca-
ions with respect to whether the reduction in GVHD
een after CoPP administration will be associated with
reservation of the beneﬁcial graft-versus-leukemia
ffect, and experiments are planned to address this
ssue.
Our data demonstrate that 2 injections of CoPP to
MT recipients before the infusion of bone marrow
nd T cells result in nearly complete abrogation of
VHD mortality. This protective effect is associated
ith signiﬁcant reductions in serum cytokine levels
nd injury to the intestinal tract but does not affect
onor T-cell responses after BMT. These ﬁndings
uggest that the induction of HO-1 expression before
ull-intensity conditioning may represent a novel,
on–cross-reactive strategy to reduce the severity of
VHD and improve outcomes after allogeneic BMT.
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